Cartesian Therapeutics Inc RNAC:NASDAQ

RT Quote | USD
Last | 05/21/24 EDT
24.60quote price arrow down-1.23 (-4.76%)
Volume
163,091
52 week range
11.66 - 42.60
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close25.83
  • 52 Week High42.60
  • 52 Week High Date11/27/23
  • 52 Week Low11.66
  • 52 Week Low Date04/08/24

Key Stats

  • Market Cap437.783M
  • Shares Out17.80M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta0.55
  • YTD % Change18.94

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close25.83
  • 52 Week High42.60
  • 52 Week High Date11/27/23
  • 52 Week Low11.66
  • 52 Week Low Date04/08/24
  • Market Cap437.783M
  • Shares Out17.80M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta0.55
  • YTD % Change18.94

RATIOS/PROFITABILITY

  • EPS (TTM)-48.02
  • P/E (TTM)-0.51
  • Fwd P/E (NTM)-4.90
  • EBITDA (TTM)-79.822M
  • ROE (TTM)-49.79%
  • Revenue (TTM)25.906M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-983.83%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/15/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cartesian Therapeutics Inc

 

Profile

MORE
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen...
Carrie Cox
Independent Chairman of the Board
Carsten Brunn Ph.D.
President, Chief Executive Officer, Director
Metin Kurtoglu
Chief Operating Officer
Blaine Davis
Chief Financial Officer
Address
65 Grove Street
Watertown, MA
02472
United States

Top Peers

SYMBOLLASTCHG%CHG
OABI
OmniAb Inc
4.32-0.07-1.59%
VERV
Verve Therapeutics Inc
5.54-0.41-6.89%
TCRX
TScan Therapeutics Inc
9.28+0.09+0.98%
CCCC
C4 Therapeutics Inc
5.76+0.14+2.49%
OCGN
Ocugen Inc
1.85-0.07-3.65%